Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022GlobeNewsWire • 07/28/22
Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022GlobeNewsWire • 07/19/22
Access to Myriad Genetics' GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled TrialGlobeNewsWire • 07/12/22
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) IntegrationGlobeNewsWire • 06/23/22
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor GenomePRNewsWire • 06/22/22
Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare ConferenceGlobeNewsWire • 06/09/22
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022GlobeNewsWire • 05/26/22
Myriad Genetics, Inc. (MYGN) CEO Paul Diaz on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022GlobeNewsWire • 05/05/22
Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare ConferenceGlobeNewsWire • 05/04/22
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology SolutionsGlobeNewsWire • 05/03/22
Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022GlobeNewsWire • 04/28/22
2 Out of 3 Women With Depression or Anxiety Say They've Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking TreatmentGlobeNewsWire • 04/26/22
Myriad Genetics (MYGN) to Offer Companion Diagnostic for LynparzaZacks Investment Research • 03/14/22
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient CareGlobeNewsWire • 03/14/22
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast CancerGlobeNewsWire • 03/12/22
Myriad Genetics Named to Fast Company's Annual List of World's Most Innovative CompaniesGlobeNewsWire • 03/08/22
Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care ConferenceGlobeNewsWire • 03/02/22